中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

90 records (took 0.035 seconds)

    METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    13.
    发明申请
    METHODS FOR INCREASING THERMOGENIC ADIPOCYTES 有权
    增加热原性ADIPOCY的方法

    公开(公告)号：US20100310577A1

    公开(公告)日：2010-12-09

    申请号：US12796332

    申请日：2010-06-08

    Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    IPC: A61K39/395 ,  A61K38/16 ,  A61K31/7088 ,  A61K38/18 ,  A61P3/00

    CPC classification number: C07K16/40 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/1796 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P21/00 ,  C07K14/71 ,  C07K2319/30 ,  C12N5/0602

    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

    Abstract translation: 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗淋巴结，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。

    Variants derived from ActRIIB and uses therefor
    14.
    发明授权
    Variants derived from ActRIIB and uses therefor 有权
    衍生自ActRIIB的变体并用于此

    公开(公告)号：US07842663B2

    公开(公告)日：2010-11-30

    申请号：US12012652

    申请日：2008-02-04

    Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    IPC: A61K38/00 ,  A61K38/16 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71

    CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K14/705 ,  C07K14/72 ,  C07K16/18 ,  C07K2319/30 ,  C07K2319/70

    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

    Abstract translation: 在某些方面，本发明提供用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪和/或神经元组织的生长的组合物和方法。 本发明还提供筛选调节ActRIIB蛋白和/或ActRIIB配体的活性的化合物的方法。 本文提供的组合物和方法可用于治疗与ActRIIB蛋白和/或ActRIIB配体的异常活性相关的疾病。

    Pharmaceutical preparations comprising an ALK1-Fc fusion protein
    19.
    发明授权
    Pharmaceutical preparations comprising an ALK1-Fc fusion protein 有权
    包含ALK1-Fc融合蛋白的药物制剂

    公开(公告)号：US08158584B2

    公开(公告)日：2012-04-17

    申请号：US12434598

    申请日：2009-05-01

    Applicant: Asya Grinberg ,  John Knopf ,  Ravindra Kumar ,  Robert S. Pearsall ,  Jasbir Seehra ,  Kristian Pietras

    Inventor： Asya Grinberg ,  John Knopf ,  Ravindra Kumar ,  Robert S. Pearsall ,  Jasbir Seehra ,  Kristian Pietras

    IPC: A61K38/00 ,  A61K38/16

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/76 ,  C07K2319/32

    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.

    Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 此外，本公开表明ALK1的抑制剂可用于增加血管化组织（包括肿瘤和视网膜）中的周细胞覆盖。 本公开还鉴定了ALK1的配体，并证明这些配体具有促血管生成活性，并且描述了抑制受体 - 配体相互作用的抗体。

Patent Agency Ranking